Equities Analysts Offer Predictions for Surrozen Q1 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Equities research analysts at Lifesci Capital reduced their Q1 2026 earnings per share estimates for Surrozen in a report issued on Monday, March 23rd. Lifesci Capital analyst P. Dolezal now expects that the company will post earnings per share of ($2.06) for the quarter, down from their previous estimate of ($1.82). The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. Lifesci Capital also issued estimates for Surrozen’s Q2 2026 earnings at ($2.10) EPS, Q3 2026 earnings at ($2.17) EPS, Q4 2026 earnings at ($1.23) EPS and FY2026 earnings at ($4.73) EPS.

SRZN has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 target price on shares of Surrozen in a research note on Tuesday. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target (up from $32.00) on shares of Surrozen in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.00.

Surrozen Price Performance

Shares of SRZN opened at $26.14 on Thursday. Surrozen has a 1-year low of $5.90 and a 1-year high of $29.59. The company has a 50-day moving average of $24.34 and a 200 day moving average of $18.81. The firm has a market capitalization of $224.02 million, a price-to-earnings ratio of -0.78 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). The company had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%.

Hedge Funds Weigh In On Surrozen

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares in the last quarter. Stonepine Capital Management LLC boosted its position in shares of Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Stempoint Capital LP grew its stake in Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after buying an additional 445,713 shares during the last quarter. Armistice Capital LLC acquired a new position in Surrozen during the 2nd quarter valued at about $536,000. Finally, Braidwell LP acquired a new position in Surrozen during the 2nd quarter valued at about $1,252,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder Group Gp Lp Column III acquired 18,052 shares of Surrozen stock in a transaction that occurred on Tuesday, January 20th. The stock was purchased at an average price of $19.60 per share, for a total transaction of $353,819.20. Following the purchase, the insider directly owned 1,016,658 shares in the company, valued at $19,926,496.80. The trade was a 1.81% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Tcg Crossover Gp Ii, Llc bought 106,658 shares of the firm’s stock in a transaction that occurred on Tuesday, March 24th. The shares were purchased at an average cost of $24.69 per share, with a total value of $2,633,386.02. Following the transaction, the insider directly owned 736,554 shares of the company’s stock, valued at $18,185,518.26. The trade was a 16.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 330,291 shares of company stock valued at $7,478,785. Insiders own 45.18% of the company’s stock.

Surrozen News Summary

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Major shareholder TCG Crossover GP II purchased 106,658 shares on March 24 at an average $24.69, increasing its stake ~16.9% to 736,554 shares — a strong insider-buy signal that can support the stock. SEC Filing
• Positive Sentiment: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90, a smaller follow-on purchase that further signals insider confidence. SEC Filing
• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating with a $40 price target — a materially higher valuation that may attract buyers. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and raised its target to $36. Its analyst also issued a FY2030 EPS forecast (-$3.54), notably less negative than the broader consensus, signaling a more optimistic long-term view. TickerReport
• Neutral Sentiment: Short-interest reports for March show zero shorted shares and a 0.0 days-to-cover metric, but the entries include NaN and look inconsistent — treat this as unreliable data rather than a clear market signal.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.